Download PDF
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2020; 80(01): 48-59
DOI: 10.1055/a-1030-4546
GebFra Science
Review/Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Prophylaxe und Therapie venöser thrombotischer Ereignisse (VTE) in Schwangerschaft und Wochenbett

Article in several languages: English | deutsch
Christoph Sucker
Gerinnungszentrum Berlin Dr. Sucker, Berlin, Germany
› Author Affiliations
Further Information

Publication History

received 08 February 2019
revised 21 August 2019

accepted 17 October 2019

Publication Date:
26 November 2019 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Venöse Thromboembolien und Lungenembolien sind eine der Hauptursachen von Morbidität und Mortalität in der Schwangerschaft. Das durch die physiologischen Veränderungen während der Schwangerschaft bedingte erhöhte Risiko thrombotischer Ereignisse rechtfertigt alleine noch keine medikamentöse antithrombotische Prophylaxe. Kommen allerdings weitere Risikofaktoren wie Thrombosen in der Vorgeschichte, hormonelle Stimulation im Rahmen einer Kinderwunschbehandlung, Thrombophilie, höheres Schwangerenalter, gravierendes Übergewicht oder prädisponierende Begleiterkrankungen hinzu, muss das Thromboserisiko – nach Möglichkeit von einem Gerinnungsspezialisten – neu bewertet und gegebenenfalls eine medikamentöse Prophylaxe eingeleitet werden. Niedermolekulare Heparine (NMH) sind die Standardmedikation zur Prophylaxe und Therapie thrombotischer Ereignisse in Schwangerschaft und Wochenbett. Eine in der Schwangerschaft begonnene medikamentöse Thromboseprophylaxe wird aufgrund des im Wochenbett gipfelnden Thromboserisikos in der Regel für ca. 6 Wochen nach der Entbindung fortgeführt. Gleiches gilt für die therapeutische Antikoagulation nach Auftreten eines thrombotischen Ereignisses in der Schwangerschaft; hier sollte auch eine Mindestdauer der Therapie von 3 Monaten eingehalten werden. In der Stillzeit kommen NMH oder das orale Antikoagulans Warfarin in Betracht; beide Wirkstoffe gehen nicht in die Muttermilch über.

Schlüsselwörter

Thromboembolien - Schwangerschaft - Antikoagulation - niedermolekulare Heparine - orale Antikoagulanzien
 

  • References/Literatur

  • 1 Say L, Chou D, Gemmill A. et al. Global causes of maternal deaths: a WHO systematic analysis. Lancet Glob Health 2014; 2: e329-e338
    PubMedGoogle Scholar
  • 2 De Stefano V, Martinelli I, Rossi E. et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol 2006; 135: 386-391
    CrossrefPubMedGoogle Scholar
  • 3 Gherman RB, Goodwin TM, Leung B. et al. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol 1999; 94: 730-734
    PubMedGoogle Scholar
  • 4 Heit JA, Kobbervig CE, James AH. et al. Trends in the incidence of venous thromboembolism during pregnancy and postpartum: a 30-year population-based study. Ann Intern Med 2005; 143: 697-706
    CrossrefPubMedGoogle Scholar
  • 5 Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium – a register-based case-control study. Am J Obstet Gynecol 2008; 198: 233.e1-233.e7
    CrossrefPubMedGoogle Scholar
  • 6 Lindqvist P, Dahlbäck B, Marsal K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999; 94: 595-599
    PubMedGoogle Scholar
  • 7 Sharma S, Monga D. Venous thromboembolism during pregnancy and the post-partum period: Incidence and risk factors in a large Victorian health service. Aust N Z J Obstet Gynaecol 2008; 48: 44-49
    CrossrefPubMedGoogle Scholar
  • 8 Simpson EL, Lawrenson RA, Nighingale AL. et al. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG 2001; 108: 56-60
    PubMedGoogle Scholar
  • 9 Sucker C. Klinische Hämostaseologie in der Gynäkologie und Geburtshilfe. Berlin, Boston: De Gruyter; 2017
    Google Scholar
  • 10 Zotz RB, Sucker C, Gerhardt A. Thrombophile Hämostasestörung in der Schwangerschaft. Haemostaseologie 2008; 28: 455-464
    PubMedGoogle Scholar
  • 11 Kourlaba G, Relakis J, Kontodimas S. et al. A systematic review and meta-analysis of the epidemiology and burden of venous thromboembolism among pregnant women. Int J Gynaecol Obstet 2016; 132: 4-10
    CrossrefPubMedGoogle Scholar
  • 12 Parunov LA, Soshitova NP, Ovanesov MV. et al. Epidemiology of venous thromboembolism (VTE) associated with pregnancy. Birth Defects Res C Embryo Today 2015; 105: 167-184
    CrossrefPubMedGoogle Scholar
  • 13 Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003; 16: 153-168
    CrossrefPubMedGoogle Scholar
  • 14 Cadroy Y, Grandjean H, Pichon J. et al. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Ostet Gynaecol 1993; 100: 416-420
    PubMedGoogle Scholar
  • 15 Eichinger S. D-dimer testing in pregnancy. Semin Vasc Med 2005; 5: 375-378
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Hoke M, Kyrle PA, Philipp K. et al. Prospective evaluation of coagulation activation in pregnant women receiving low-molecular weight heparin. Thromb Haemost 2004; 91: 935-940
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Cerneca F, Ricci G, Simeone R. et al. Coagulation and fibrinolysis changes in normal pregnancy. Increased level of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol 1997; 73: 31-36
    CrossrefPubMedGoogle Scholar
  • 18 Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol 2014; 5: 65
    PubMedGoogle Scholar
  • 19 Danilenko-Dixon DR, Heit JA, Silverstein MD. et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol 2001; 184: 104-110
    CrossrefPubMedGoogle Scholar
  • 20 Brill-Edwards P, Ginsberg JS, Gent M. et al. Recurrence of a clot in This Pregnancy Study Group. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000; 343: 1439-1444
    CrossrefPubMedGoogle Scholar
  • 21 Pabinger I, Grafenhofer H, Kyrle PA. et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 2002; 100: 1060-1062
    CrossrefPubMedGoogle Scholar
  • 22 Pabinger I, Grafenhofer H, Kaider A. et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005; 3: 949-954
    CrossrefPubMedGoogle Scholar
  • 23 Gerhardt A, Scharf RE, Beckmann RE. et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342: 374-380
    CrossrefPubMedGoogle Scholar
  • 24 Gerhardt A, Scharf RE, Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost 2003; 90: 77-85
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Ogunyemi D, Cuellar F, Ku W. et al. Association between inherited thrombophilias, antiphospholipid antibodies, and lipoprotein A levels and venous thromboembolism in pregnancy. Am J Perinatol 2003; 20: 17-24
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Pomp ER, Lenselink AM, Rosendaal FR. et al. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6: 632-637
    CrossrefPubMedGoogle Scholar
  • 27 Robertson L, Wu O, Langhorne P. et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132: 171-196
    CrossrefPubMedGoogle Scholar
  • 28 Rosendaal FR, Koster T, Vandenbroucke JP. et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-1508
    CrossrefPubMedGoogle Scholar
  • 29 Rosendaal FR. Risk factors for venous thrombosis: Prevalence, risk, and interaction. Sem Hematol 1997; 34: 171-187
    PubMedGoogle Scholar
  • 30 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-1231
    CrossrefPubMedGoogle Scholar
  • 31 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306
    CrossrefPubMedGoogle Scholar
  • 32 Royal College of Obstetricians and Gynaecologists. Reducing the risk of venous thromboembolism during pregnancy and the puerperium. Green-Top Guideline No. 37a, 2015. Online: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf last access: 01.06.2019
    PubMedGoogle Scholar
  • 33 Larsen TB, Sørensen HT, Gislum M. et al. Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: a population-based nested case-control study. Thromb Res 2007; 120: 505-509
    CrossrefPubMedGoogle Scholar
  • 34 Liston F, Davies GA. Thromboembolism in the obese pregnant woman. Semin Perinatol 2011; 35: 330-334
    CrossrefPubMedGoogle Scholar
  • 35 Butwick AJ, Bentley J, Leonard SA. et al. Prepregnancy maternal body mass index and venous thromboembolism: a population-based cohort study. BJOG 2019; 126: 581-588
    CrossrefPubMedGoogle Scholar
  • 36 Bates SM, Greer IA, Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl.): e691S-e736S
    CrossrefPubMedGoogle Scholar
  • 37 James A. Committee on Practice Bulletins–Obstetrics. Practice bulletin no. 123: thromboembolism in pregnancy. Obstet Gynecol 2011; 118: 718-729
    CrossrefPubMedGoogle Scholar
  • 38 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). S3-Leitlinie Prophylaxe der venösen Thromboembolie (VTE), 2. komplett überarbeitete Auflage, Stand 15.10.2015. Online: https://www.awmf.org/leitlinien/detail/ll/003-001.html last access: 01.07.2019
    PubMedGoogle Scholar
  • 39 Rova K, Passmark H, Lindqvist PG. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril 2012; 97: 95-100
    CrossrefPubMedGoogle Scholar
  • 40 Henriksson P, Westerlund E, Wallén H. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ 2013; 346: e8632
    CrossrefPubMedGoogle Scholar
  • 41 Grandone E, Di Micco PP, Villani M. et al. RIETE Investigators. Venous Thromboembolism in Women Undergoing Assisted Reproductive Technologies: Data from the RIETE Registry. Thromb Haemost 2018; 118: 1962-1968
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Chan WS, Dixon ME. The “ART” of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res 2008; 121: 713-726
    CrossrefPubMedGoogle Scholar
  • 43 Hansen AT, Erichsen R, Horváth-Puhó E. et al. Inflammatory bowel disease and venous thromboembolism during pregnancy and the postpartum period. J Thromb Haemost 2017; 15: 702-708
    CrossrefPubMedGoogle Scholar
  • 44 Fornaro R, Caristo G, Stratta E. et al. Thrombotic complications in inflammatory bowel diseases. G Chir 2019; 40: 14-19
    PubMedGoogle Scholar
  • 45 Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther 2014; 16: 435 doi:10.1186/s13075-014-0435-y
    CrossrefPubMedGoogle Scholar
  • 46 Sweetland S, Green J, Liu B. et al. Million Women Study collaborators. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ 2009; 339: b4583 doi:10.1136/bmj.b4583
    CrossrefPubMedGoogle Scholar
  • 47 Bates SM. Management of pregnant women with thrombophilia or a history of venous thromboembolism. Hematol Am Soc Hematol Educ Program 2007; 2007: 143-150
    CrossrefPubMedGoogle Scholar
  • 48 Bates SM. Pregnancy-associated venous thromboembolism: prevention and treatment. Semin Hematol 2011; 48: 271-284
    CrossrefPubMedGoogle Scholar
  • 49 James AH, Jamison MG, Brancazio LR. et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194: 1311-1315
    CrossrefPubMedGoogle Scholar
  • 50 James AH. Pregnancy-associated thrombosis. Hematology Am Soc Hematol Educ Program 2009; 277-285
    PubMedGoogle Scholar
  • 51 James AH. Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol 2009; 29: 326-331
    CrossrefPubMedGoogle Scholar
  • 52 Chauleur C, Gris JC, Laporte S. et al. Use of the Delphi method to facilitate antithrombotics prescription during pregnancy. Thromb Res 2010; 126: 88-92
    CrossrefPubMedGoogle Scholar
  • 53 Royal College of Obstetricians and Gynaecologists. Thromboembolic disease in pregnancy and the puerperium: acute management. Green-top Guideline No. 37b, April 2015. Online: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37b.pdf last access: 01.06.2019
    PubMedGoogle Scholar
  • 54 Linnemann B, Scholz U, Rott H. et al. Working Group in Womenʼs Health of the Society of Thrombosis and Hemostasis. Treatment of pregnancy-associated venous thromboembolism – position paper from the Working Group in Womenʼs Health of the Society of Thrombosis and Haemostasis (GTH). Vasa 2016; 45: 103-118
    CrossrefPubMedGoogle Scholar
  • 55 Chan WS, Rey E. Kent NE; VTE in Pregnancy Guideline Working Group, Society of Obstetricians and Gynecologists of Canada. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can 2014; 36: 527-553
    CrossrefPubMedGoogle Scholar
  • 56 DʼIppolito S, Ortiz AS, Veglia M. et al. Low molecular weight heparin in obstetric care: a review of the literature. Reprod Sci 2011; 18: 602-613
    CrossrefPubMedGoogle Scholar
  • 57 Lepercq J, Conrad J, Borel-Derlon A. et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001; 108: 1134-1140
    PubMedGoogle Scholar
  • 58 Sanson BJ, Lensing AW, Prins MH. et al. Safety of low-molecular weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668-672
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Shapiro NL, Kominiarek MA, Nutescu EA. et al. Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience. Pharmacotherapy 2011; 31: 678-685
    CrossrefPubMedGoogle Scholar
  • 60 Johansen KB, Balchen T. Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?. Exp Hematol Oncol 2013; 2: 21 doi:10.1186/2162-3619-2-21
    CrossrefPubMedGoogle Scholar
  • 61 Le Templier G, Rodger MA. Heparin-induced osteoporosis and pregnancy. Curr Opin Pulm Med 2008; 14: 403-407
    CrossrefPubMedGoogle Scholar
  • 62 Ciurzyński M, Jankowski K, Pietrzak B. et al. Use of fondaparinux in a pregnant woman with pulmonary embolism and heparin-induced thrombocytopenia. Med Sci Monit 2011; 17: 56-59
    PubMedGoogle Scholar
  • 63 Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004; 350: 1914-1915
    CrossrefPubMedGoogle Scholar
  • 64 Gerhardt A, Zotz RB, Stockschlaeder M. et al. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids. Thromb Haemost 2007; 97: 496-497
    Article in Thieme ConnectPubMedGoogle Scholar
  • 65 Knol HM, Schultinge L, Erwich JJ. et al. Fondaparinux as an alternative anticoagulant therapy during pregnancy. J Thromb Haemost 2010; 8: 1876-1879
    CrossrefPubMedGoogle Scholar
  • 66 Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 2005; 93: 63-69
    Article in Thieme ConnectPubMedGoogle Scholar
  • 67 Magnani HN. An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran). Thromb Res 2010; 125: 297-302
    CrossrefPubMedGoogle Scholar
  • 68 Holzgreve W, Carey JC, Hall BD. Warfarin-induced fetal abnormalities. Lancet 1976; 2(7991): 914-915
    PubMedGoogle Scholar
  • 69 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). S2-Leitlinie: Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Aktueller Stand: 10.10.2015 Online: https://www.awmf.org/uploads/tx_szleitlinien/065-002l_S2k_VTE_2016-01.pdf last access: 01.07.2019
    PubMedGoogle Scholar